While SGLT2 inhibitors were originally developed to treat hyperglycemia, glycated hemoglobin (HbA1c) reduction is relatively modest and is not the major mediator of the cardiovascular benefit, as demonstrated through mediation analysis10 and meta-regression analysis11 of the cardiovascular outcome trials, and mediation analysis of cardiovascular disease outcomes in genetic variants causing SGLT2 inhibition.12 Here, SLC5A2 is linked to Hyperglycemia.